FDA 483 - Minaris Regenerative Medicine, LLC - September 29, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Minaris Regenerative Medicine, LLC in Allendale, NJ, a contract manufacturer of gene therapy drugs, identified three significant observations. The firm failed to establish adequate written procedures for production and process controls, particularly regarding deviation documentation for LYFGENIA manufacturing. Additionally, there were no written procedures for handling post-marketing adverse drug experiences for their product, lovo-cel (LYFGENIA), and batch records lacked documentation of major equipment used in production.
ID · ac4c71cd-5f2b-4894-aeda-0eaff58988ab